Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Treffer: 22
Order by:- [r.161] Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA), Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI), Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI), Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI), Österreichische Gesellschaft für Pneumologie (ÖGP) in co-operation with the German, Austrian, and Swiss ARIA groups, and the European Academy of Allergy and Clinical Immunology (EAACI) (1)
- [r.152] How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers (2)
- [r.143] Treatments of cold urticaria: a systematic review (0)
- [r.119] Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion (0)
- [r.105] Current and future therapies for treating chronic spontaneous urticaria (0)
- [r.094] Omalizumab for the treatment of chronic urticaria (0)
- [r.092] The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria (0)
- [r.080] Pharmacotherapy of chronic spontaneous urticaria (0)
- [o.394] Anaphylaxis to mepolizumab and omalizumab in a single patient – is polysorbate the culprit? (1)
- [o.386] Response of omalizumab in normocomplementemic urticarial vasculitis (0)
- [o.347] Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America (0)
- [o.341] Real-life treatment of cholinergic urticaria with omalizumab (0)
- [o.339] Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double‐blind, placebo‐controlled study (0)
- [o.334] Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab (1)
- [o.298] Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data (1)
- [o.297] The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change (0)
- [o.269] Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcɛRI-positive cells in the skin (0)
- [o.261] Effect of omalizumab on angioedema in H1-antihistamine resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial (1)
- [o.242] Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials (0)
- [o.211] Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy (0)
(Last update: 11.2020)
| Number of publications (original work and reviews) in peer-reviewed journals: | 582 |
| Number of original publications in peer-reviewed journals: | 418 |
| Number of reviews in peer-reviewed journals: | 164 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 3203,30 |
| Cumulative IF for original publications in peer-reviewed journals: | 2563,44 |
| Cumulative IF for reviews in peer-reviewed journals: | 639,86 |
| Citations, Hirsch index: (view on Web of Science) | 22913, 76 |